Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SRZN
$25.88
$
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Next Earnings
2026-02-25
Beta
0.585
Average Volume
Market Cap
Last Dividend
CIK
0001824893
ISIN
US86889P2083
CUSIP
86889P109
CEO
Craig C. Parker
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
40
IPO Date
2021-01-11
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on February 17, 2026, Surrozen granted a non-statutory stock option for an aggregate of 3,070 shares of Surrozen common stock to a recently hired non-executive employee as an inducement material to their acceptance of employment with Surrozen. | GlobeNewsWire | 2026-02-23 16:30:00 |
| Surrozen (NASDAQ:SRZN) & Galmed Pharmaceuticals (NASDAQ:GLMD) Financial Review | Surrozen (NASDAQ: SRZN - Get Free Report) and Galmed Pharmaceuticals (NASDAQ: GLMD - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Institutional and Insider Ownership 66.6% of Surrozen shares | Defense World | 2026-02-14 01:28:54 |
| Surrozen to Present at Upcoming Healthcare Investor Conference | SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference. | GlobeNewsWire | 2026-02-05 16:05:00 |
| Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 18,052 Shares of Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were acquired at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the insider owned 1,016,658 | Defense World | 2026-01-21 04:39:29 |
| Surrozen (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Acquires 11,893 Shares of Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 11,893 shares of the company's stock in a transaction that occurred on Thursday, January 15th. The stock was acquired at an average cost of $19.89 per share, with a total value of $236,551.77. Following the purchase, the insider directly owned | Defense World | 2026-01-21 04:39:28 |
| Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 18,052 Shares | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 18,052 shares of the firm's stock in a transaction on Tuesday, January 20th. The shares were purchased at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the director directly owned 1,016,658 shares of | Defense World | 2026-01-21 04:39:27 |
| Surrozen (NASDAQ:SRZN) Director Tim Kutzkey Acquires 11,893 Shares | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 11,893 shares of Surrozen stock in a transaction dated Thursday, January 15th. The stock was bought at an average price of $19.89 per share, with a total value of $236,551.77. Following the acquisition, the director directly owned 1,005,732 shares of the company's stock, valued | Defense World | 2026-01-21 04:39:27 |
| Surrozen (NASDAQ:SRZN) Director Buys $110,404.77 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey acquired 5,523 shares of the business's stock in a transaction that occurred on Wednesday, January 14th. The shares were acquired at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the director directly owned 999,429 shares in the | Defense World | 2026-01-18 05:40:56 |
| Surrozen (NASDAQ:SRZN) Major Shareholder Acquires $110,404.77 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III acquired 5,523 shares of the stock in a transaction dated Wednesday, January 14th. The shares were bought at an average cost of $19.99 per share, with a total value of $110,404.77. Following the transaction, the insider directly owned 999,429 shares of | Defense World | 2026-01-18 05:40:53 |
| Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Buys $246,906.00 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III bought 12,470 shares of the company's stock in a transaction on Tuesday, January 13th. The shares were bought at an average cost of $19.80 per share, for a total transaction of $246,906.00. Following the transaction, the insider directly owned 996,502 shares | Defense World | 2026-01-18 05:40:49 |
| Surrozen (NASDAQ:SRZN) Director Buys $246,906.00 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey purchased 12,470 shares of the business's stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of $19.80 per share, for a total transaction of $246,906.00. Following the acquisition, the director owned 996,502 shares of the company's | Defense World | 2026-01-18 05:40:49 |
| Insider Buying: Surrozen (NASDAQ:SRZN) Director Purchases $300,339.00 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) Director Tim Kutzkey bought 15,100 shares of the business's stock in a transaction on Tuesday, January 6th. The stock was bought at an average cost of $19.89 per share, with a total value of $300,339.00. Following the transaction, the director owned 989,893 shares in the company, valued at | Defense World | 2026-01-11 04:56:44 |
| Surrozen (NASDAQ:SRZN) Major Shareholder Buys $300,339.00 in Stock | Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Group Gp Lp Column III purchased 15,100 shares of the firm's stock in a transaction dated Tuesday, January 6th. The stock was purchased at an average cost of $19.89 per share, for a total transaction of $300,339.00. Following the acquisition, the insider owned 989,893 shares of | Defense World | 2026-01-11 04:56:44 |
| Surrozen to Present at Upcoming Healthcare Investor Conferences | SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at two upcoming healthcare investor conferences. | GlobeNewsWire | 2025-11-25 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G/A | 2026-02-05 | 2026-02-05 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| SC 13G | 2026-02-02 | 2026-02-02 | View Filing |
| 8-K | 2026-01-30 | 2026-01-30 | View Filing |
| 3 | 2026-01-28 | 2026-01-28 | View Filing |
| 4 | 2026-01-26 | 2026-01-26 | View Filing |
| SC 13D/A | 2026-01-22 | 2026-01-22 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-20 | 2026-01-20 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-15 | 2026-01-15 | View Filing |
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-08 | 2026-01-08 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-08 | 2025-12-08 | View Filing |
| 4 | 2025-12-02 | 2025-12-02 | View Filing |
| SC 13G | 2025-11-20 | 2025-11-20 | View Filing |
| 4 | 2025-11-17 | 2025-11-17 | View Filing |
| 4 | 2025-11-13 | 2025-11-13 | View Filing |
| 3 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-11-07 | 2025-11-07 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-08-29 | 2025-08-29 | View Filing |
| 424B5 | 2025-08-29 | 2025-08-29 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-13 | 2025-08-13 | View Filing |
| S-8 | 2025-08-08 | 2025-08-08 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| EFFECT | 2025-05-27 | 2025-05-27 | View Filing |
| S-3 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| 4 | 2025-05-05 | 2025-05-05 | View Filing |
| EFFECT | 2025-05-02 | 2025-05-02 | View Filing |
| 424B5 | 2025-05-01 | 2025-05-01 | View Filing |
| 424B5 | 2025-04-24 | 2025-04-24 | View Filing |
| S-3 | 2025-04-23 | 2025-04-23 | View Filing |
| D | 2025-04-08 | 2025-04-08 | View Filing |
| SC 13G | 2025-04-02 | 2025-04-02 | View Filing |
| ARS | 2025-04-02 | 2025-04-02 | View Filing |
| SC 13G | 2025-04-02 | 2025-04-02 | View Filing |
| DEFA14A | 2025-04-02 | 2025-04-02 | View Filing |
| DEF 14A | 2025-04-02 | 2025-04-02 | View Filing |
| S-8 | 2025-03-31 | 2025-03-31 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| SC 13G | 2025-03-31 | 2025-03-31 | View Filing |
| SC 13D/A | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 3 | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-28 | 2025-03-28 | View Filing |
| 8-K | 2025-03-28 | 2025-03-28 | View Filing |
| 4 | 2025-03-25 | 2025-03-25 | View Filing |
| 4 | 2025-03-25 | 2025-03-25 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-22 | 2025-01-22 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 9,435.42% | 0.78 | 24 | 1.01 | 1.25 | 1867.23 |
| Genetic Strat | 7,568.20% | 0.96 | 37 | 0.91 | 1.3 | 0 |
| Buy & Hold | 7,568.20% | 0.96 | 37 | 0.91 | 1.3 | 7568.2 |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxx | xxxxxx% | xxxx | xx | xxxx | xxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxx | x% | x | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxxxx |